Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?

被引：7

作者：

Signorelli, Diego ^{[1
]}

Macerelli, Marianna ^{[1
]}

Proto, Claudia ^{[1
]}

Vitali, Milena ^{[1
]}

Cona, Maria Silvia ^{[1
]}

Agustoni, Francesco ^{[1
]}

Zilembo, Nicoletta ^{[1
]}

Platania, Marco ^{[1
]}

Trama, Annalisa ^{[2
]}

Gallucci, Rosaria ^{[1
]}

Ganzinelli, Monica ^{[1
]}

Pelosi, Giuseppe ^{[3
]}

Pastorino, Ugo ^{[4
]}

de Braud, Filippo ^{[1
]}

Garassino, Marina Chiara ^{[1
]}

Lo Russo, Giuseppe ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Prevent & Predict Med, Milan, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Dept Pathol & Lab Med, Milan, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Div Thorac Surg, Milan, Italy

来源：

TUMORI JOURNAL | 2016年 / 102卷 / 01期

关键词：

Chemotherapy; Immunotherapy; Malignant pleural mesothelioma; Target therapy; PHASE-III TRIAL; PEMETREXED PLUS CISPLATIN; PREVIOUSLY TREATED PATIENTS; EUROPEAN-ORGANIZATION; GEMCITABINE TREATMENT; TRIMODALITY THERAPY; PRETREATED PATIENTS; IMATINIB MESYLATE; SUPPORTIVE CARE; CLINICAL-TRIAL;

D O I：

10.5301/tj.5000436

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant pleural mesothelioma is a rare cancer with a cause-effect relationship to asbestos exposure. The prognosis is poor and chemotherapy seems the best treatment option. In the last two decades a deeper understanding of mesothelioma carcinogenesis and invasiveness mechanisms has prompted research efforts to test new agents in patients with malignant pleural mesothelioma, but the results have been modest. Attractive preclinical data disappointed in subsequent experimental phases. Other promising agents failed to improve patient outcomes due to high toxicity. Interesting suggestions have come from preliminary data on immunotherapy. Several trials are ongoing and the results are eagerly awaited. The aim of this review is to discuss the most recent news on systemic therapy for advanced malignant pleural mesothelioma.

引用

页码：18 / 30

页数：13

共 92 条

[1] The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma [J].

Ak, Guntulu ;

Metintas, Selma ;

Akarsu, Muhittin ;

Metintas, Muzaffer .

BMC CANCER, 2015, 15

[2] A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma [J].

Arrieta, Oscar ;

Lopez-Macias, Diego ;

Mendoza-Garcia, Victor-Osvaldo ;

Bacon-Fonseca, Ludwing ;

Munoz-Montano, Wendy ;

Macedo-Perez, Eleazar-Omar ;

Muniz-Hernandez, Sae ;

Blake-Cerda, Monika ;

Corona-Cruz, Jose-Francisco .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) :975-982

[3] Malignant Pleural Mesothelioma: From the Bench to the Bedside [J].

Astoul, P. ;

Roca, E. ;

Galateau-Salle, F. ;

Scherpereel, A. .

RESPIRATION, 2012, 83 (06) :481-493

[4] Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy [J].

Boeluekbas, Servet ;

Manegold, Christian ;

Eberlein, Michael ;

Bergmann, Thomas ;

Fisseler-Eckhoff, Annette ;

Schirren, Joachim .

LUNG CANCER, 2011, 71 (01) :75-81

[5] Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer? [J].

Brahmer, Julie R. .

SEMINARS IN ONCOLOGY, 2014, 41 (01) :126-132

[6]

Buikhuisen WA, 2013, J CLIN ONCOL S, V31

[7] Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study [J].

Buikhuisen, Wieneke A. ;

Burgers, Jacobus A. ;

Vincent, Andrew D. ;

Korse, Catharina M. ;

van Klaveren, Rob J. ;

Schramel, Franz M. N. H. ;

Pavlakis, Nick ;

Nowak, Anna K. ;

Custers, Frank L. J. ;

Schouwink, J. Hugo ;

Gans, Steven J. M. ;

Groen, Harry J. M. ;

Strankinga, Wim F. M. ;

Baas, Paul .

LANCET ONCOLOGY, 2013, 14 (06) :543-551

[8] Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study [J].

Byrne, MJ ;

Davidson, JA ;

Musk, AW ;

Dewar, J ;

van Hazel, G ;

Buck, M ;

de Klerk, NH ;

Robinson, BWS .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :25-30

[9] Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial [J].

Calabro, Luana ;

Morra, Aldo ;

Fonsatti, Ester ;

Cutaia, Ornella ;

Amato, Giovanni ;

Giannarelli, Diana ;

Di Giacomo, Anna Maria ;

Danielli, Riccardo ;

Altomonte, Maresa ;

Mutti, Luciano ;

Maio, Michele .

LANCET ONCOLOGY, 2013, 14 (11) :1104-1111

[10] Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium [J].

Campbell, Nicholas P. ;

Kunnavakkam, Rangesh ;

Leighl, Natasha ;

Vincent, Mark D. ;

Gandara, David R. ;

Koczywas, Marianna ;

Gitlitz, Barbara J. ;

Agamah, Edem ;

Thomas, Sachdev P. ;

Stadler, Walter M. ;

Vokes, Everett E. ;

Kindler, Hedy L. .

LUNG CANCER, 2012, 78 (01) :76-80

← 1 2 3 4 5 6 7 8 9 10 →